TheEdgeResearch
Home / Stocks / VNRX

VolitionRX Ltd (VNRX)

AMEX Healthcare Medical - Devices
$0.16 ▼ -1.58%
Market Cap
$2.0M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.16
52-Wk Range
0.1554-7.8
CEO
Cameron Reynolds
Country
US
Currency
USD

VolitionRX Ltd operates in the Medical - Devices industry of the Healthcare sector, headquartered in Henderson, NV, US. The stock last traded at $0.16, down 1.58% on the session, giving a market capitalisation of $2.0M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -698.5%. Its beta of 1.16 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.05
Price / Sales
0.57
Price / Book
-0.12
EV / EBITDA
-0.49
Gross margin
85.0%
Operating margin
-510.1%
Net margin
-698.5%
Return on equity
—
Debt / equity
-0.31
Current ratio
0.33
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange Arca
Employees
57
IPO date
2012-03-02
Headquarters
Henderson, NV, US
About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Comparable companies

VolitionRX Ltd is most often compared with the following Healthcare names:

ALGSBDSXCTSOINMBMDCXMRSNNOTVSKYEWGRXXLO
More research on VNRX
VNRX technical analysis VNRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →